In postmenopausal women with type 2 diabetes, oral hormone replacement therapy (HRT) may increase the risk of CV events.
Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, ...
The most-read article this month was a look at the new European valve guidelines, with the list fleshed out by news from ESC ...
The data aren’t definitive, but continuing OAC or switching to another drug doesn’t seem to be enough for this high-risk group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback